CA2942100A1 - Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders - Google Patents

Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders Download PDF

Info

Publication number
CA2942100A1
CA2942100A1 CA2942100A CA2942100A CA2942100A1 CA 2942100 A1 CA2942100 A1 CA 2942100A1 CA 2942100 A CA2942100 A CA 2942100A CA 2942100 A CA2942100 A CA 2942100A CA 2942100 A1 CA2942100 A1 CA 2942100A1
Authority
CA
Canada
Prior art keywords
liver
carboxy
compound
disorder
cyclopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2942100A
Other languages
English (en)
French (fr)
Inventor
Jeffrey C. Hanselman
Rai Ajit K. Srivastava
Roger S. Newton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esperion Therapeutics Inc
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of CA2942100A1 publication Critical patent/CA2942100A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2942100A 2014-03-20 2015-03-20 Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders Abandoned CA2942100A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461968082P 2014-03-20 2014-03-20
US61/968,082 2014-03-20
PCT/US2015/021677 WO2015143276A1 (en) 2014-03-20 2015-03-20 Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders

Publications (1)

Publication Number Publication Date
CA2942100A1 true CA2942100A1 (en) 2015-09-24

Family

ID=54145365

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2942100A Abandoned CA2942100A1 (en) 2014-03-20 2015-03-20 Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders

Country Status (6)

Country Link
US (1) US20170209402A1 (https=)
EP (1) EP3119388B1 (https=)
JP (1) JP6633609B2 (https=)
AU (1) AU2015231076B2 (https=)
CA (1) CA2942100A1 (https=)
WO (1) WO2015143276A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1257929A1 (zh) * 2015-11-06 2019-11-01 Gemphire Therapeutics Inc. 治疗混合性血脂异常
WO2019179494A1 (zh) * 2018-03-23 2019-09-26 深圳市塔吉瑞生物医药有限公司 取代的十五烷二酸化合物及药物组合物及其用途
CN112675159A (zh) * 2021-01-12 2021-04-20 杭州师范大学 L-苹果酸在制备防治肝脏缺血再灌注损伤药物中的应用
WO2024212248A1 (en) * 2023-04-14 2024-10-17 Meta Pharmaceuticals (Hk) Limited Substituted alkanoic-diacids compound and composition and use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2625429T3 (es) * 2003-01-23 2017-07-19 Esperion Therapeutics Inc. Compuestos de hidroxilo y composiciones para el control del colesterol y utilizaciones correspondientes
JP2013537240A (ja) * 2010-09-20 2013-09-30 カリウス セラピューティクス エスエー 糖尿病および脂質異常症の処置のための方法および組成物

Also Published As

Publication number Publication date
EP3119388A4 (en) 2017-11-22
AU2015231076A1 (en) 2016-09-22
WO2015143276A1 (en) 2015-09-24
AU2015231076B2 (en) 2020-05-21
EP3119388A1 (en) 2017-01-25
US20170209402A1 (en) 2017-07-27
JP2017509701A (ja) 2017-04-06
EP3119388B1 (en) 2020-06-17
JP6633609B2 (ja) 2020-01-22

Similar Documents

Publication Publication Date Title
TWI735546B (zh) 使用fxr促效劑之方法
KR20210137467A (ko) 담즙 염 유출 펌프 결핍을 갖는 환자에서 asbti에 대한 유전자형 및 용량-의존성 반응
CA3079259A1 (en) Ganaxolone for use in treating genetic epileptic disorders
KR102412997B1 (ko) 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법
CN115811972A (zh) 肝脏病症的组合治疗
CN116726178A (zh) sGC刺激剂在非酒精性脂肪性肝炎（NASH）治疗中的应用
EP3119388B1 (en) Carboxy-cyclopropyl undecanol compounds for treatment of liver disease and other medical disorders
CN112384220A (zh) sGC刺激剂治疗线粒体障碍的用途
EP3866799B1 (en) Compositions for treating vascular ehlers danlos syndrome
WO2019043018A1 (en) METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND REDUCING THE RISK OF CARDIOVASCULAR EVENTS
WO2019100057A1 (en) Use of morphinans for treating cocaine addiction, pruritis, and seizure disorders
CA3034956C (en) TREATMENT OF NON-ALCOHOLIC HEPATIC STEATOSE
HK40094441A (en) Compositions for treating vascular ehlers danlos syndrome
WO2022140279A1 (en) Synergistic modulators of alpha-dicarbonyl detoxification and their use for inducing weight loss and the treatment of diabetic pathologies
JP2024042690A (ja) 非アルコール性脂肪性肝疾患の予防及び／又は治療薬
CN118265542A (zh) 以回肠胆汁酸转运蛋白(ibat)抑制剂治疗以增加无事件存活期(efs)
HK40129994A (zh) 患有胆汁盐输出泵缺乏症的患者对asbti的基因型和剂量依赖性应答
HK40094581A (en) Treatment of alzheimer's disease in a particular patient population
AU2023250762A1 (en) Composition for preventing or treating pulmonary fibrosis, comprising taurodeoxycholic acid or pharmaceutically acceptable salt thereof as active ingredient
CN118139623A (zh) 顶端钠依赖型胆酸转运蛋白抑制剂(asbti)的给药方法
JP2023529311A (ja) Ｃｆｔｒ関連疾患および障害を治療する方法
HK40012462B (en) Treatment of nonalcoholic fatty liver disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200319

FZDE Discontinued

Effective date: 20220816